Skip to search formSkip to main contentSkip to account menu

ecallantide

Known as: DX-88 cpd, EPI-KAL-2 
National Institutes of Health

Related topics

Related topics

4 relations
1 ML ecallantide 10 MG/ML Injection1 ML ecallantide 10 MG/ML Injection [Kalbitor]

Narrower (1)

Kalbitor

Broader (1)

Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
First preventive mAb for hereditary angioedema
The US Food and Drug Administration has approved the first monoclonal antibody (mAb) to prevent hereditary angioedema (HEA… 
2016
2016
Shire bites deeper into rare disease space
Dublin-based Shire has agreed to buy Dyax, a company with a rare disease treatment that bolsters its current portfolio in… 
Review
2010
Review
2010
Drug Evaluation Overview of ecallantide in the treatment of hereditary angioedema types I and II
Hereditary angioedema (HAE) is a rare, debilitat‐ ing and potentially fatal disease characterized by unpredictable, acute… 
2010
2010
Ecallantide (Kalbitor): A plasma kallikrein inhibitor approved for the treatment of acute attacks of hereditary angioedema
New molecular entity: Ecallantide (Kalbitor) was approved in December 2009, to treat hereditary angioedema (HAE). 
Review
2009
Review
2009
FDA Pipeline preview, March 2009 (cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, omacetaxine)
Recent FDA action (through March 2009) related to cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide… 
2007
2007
Ecallantide efficacious in acute HAE attacks
  • 2007
  • Corpus ID: 195100493
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)